Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Krystal Biotech Stock Performance
Shares of KRYS opened at $179.25 on Friday. The company's fifty day moving average is $159.41 and its 200 day moving average is $175.26. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The stock has a market capitalization of $5.16 billion, a PE ratio of 59.95 and a beta of 0.84.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. During the same quarter in the previous year, the business posted $0.30 earnings per share. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. As a group, research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.
Institutional Investors Weigh In On Krystal Biotech
Large investors have recently bought and sold shares of the business. Entropy Technologies LP bought a new stake in Krystal Biotech in the fourth quarter worth $548,000. Summit Trail Advisors LLC bought a new position in Krystal Biotech during the third quarter valued at $1,893,000. Swiss National Bank increased its position in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $7,117,000 after acquiring an additional 2,900 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after acquiring an additional 15,545 shares during the last quarter. Finally, Citigroup Inc. increased its position in Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after acquiring an additional 13,874 shares during the last quarter. Institutional investors own 86.29% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on KRYS. HC Wainwright reissued a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus target price of $215.83.
View Our Latest Analysis on Krystal Biotech
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
